Pattern of Viral Infections among Kurdish Chemical Attack Survivors: An Observational Study
DOI:
https://doi.org/10.21928/uhdjst.v10n1y2026.pp159-164Keywords:
Chemical weapons, Iraqi Kurds, Halabja, Seroprevalence, Viral infectionAbstract
Background: Survivors of chemical attacks can experience permanent immune-related changes that can affect their vulnerability to viral infections. The paper compared seroprevalence rates of hepatotropic viruses and herpesviruses in Kurdish survivors of chemical attacks and those who were not exposed to the chemical. Methods: This observational study will involve 321 participants (a sample size of 221 survivors and 100 controls), who will be recruited in Iraqi Kurdistan, between November 2023 and May 2024. Enzyme-linked immunosorbent assay was used to test serum samples using Hepatitis B virus (HBV), Hepatitis C virus (HCV), Hepatitis D virus (HDV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), and Varicella –Zoster virus (VZV). Results: HBV positivity was detected in 5.4% of survivors and 2.0% of controls, and no significant difference was detected (P = 0.240). The seropositivity of HCV was also significantly higher among survivors (4.5% vs. 0.0%, P = 0.034). Only survivors were found to have HDV (1.4% vs. 0.0%), but this was not significant. CMV immunoglobulin G (IgG) was common in both groups (56.6% vs. 61.0%, P = 0.467), but CMV IgM was identified exclusively in survivors (7.7% vs. 0.0%, P = 0.002). The EBV IgG was very high and similar in the two groups (91.4 and 92.0, P = 1.000), but EBV IgM was uncommon and only observed in survivors (1.8 and 0.0). VZV IgG was also found to be significantly lower in survivors compared to controls (81.4% vs. 91.0% P = 0.031), whereas VZV IgM was only detected in survivors (2.7% vs. 0.0%). Conclusion: Survivors showed higher HCV seropositivity and exclusive IgM positivity in herpesviruses, which can indicate more opportunities to be exposed to the virus or altered immune regulation in chemical-attack victims.
References
M. B. A. Muhammad, S. A. Hama, K. A. M. Hawrami, S. H. Karim, G. S. Ahmed and H. M. Rahim. “Long-term health complications of chemical weapon exposure: A study on Halabja chemical attack survivors (Iraqi Kurds)”. Inhalation Toxicology, vol. 36, no. 1, pp. 26-30, 2024.
S. A. Hama and S. A. Aziz. “Hepatitis A and E seropositivity and nucleic acid detection among chemical bombardment survivors in Iraqi Kurdistan Region”. Journal of Zankoy Sulaimani-Part A, vol. 19, no. 3&4, pp. 17-24, 2017.
S. A. Hama, B. M. Al-Jaff and B. M. Mahmud. “Common Health Complains among Chemical Bombardment Survivors in Halabja”. Journal of Duhok University, vol. 12, no. 1, pp. 312-316, 2009.
F. Moradi, M. Söderberg, F. Moradi, B. Daka, A. C. Olin and M. Lärstad. “Health perspectives among Halabja’s civilian survivors of sulfur mustard exposure with respiratory symptoms-a qualitative study”. PloS One, vol. 14, no. 6, p. e0218648, 2019.
E. Darchini-Maragheh and M. Balali-Mood. “Delayed complications and long-term management of sulfur mustard poisoning: Recent advances by Iranian researchers (part I of II)”. Iranian Journal of Medical Sciences, vol. 43, no. 2, p. 103-124, 2018.
S. A. Hama, B. M. Al-Jaff and B. M. Mahmud. “The Effect of Chemical Warfare Agents on the Immune System of Survivors in Halabja”. In: International Conference on Genocide against the Kurdish People, pp. 179-183, 2008.
Institute of Medicine (US). “Committee on the Survey of the Health Effects of Mustard Gas and Lewisite. Other physiological effects of mustard agents and Lewisite”. In: C. M. Pechura and D. P. Rall, editors. Veterans at Risk: The Health Effects of Mustard Gas and Lewisite. Ch. 10. National Academies Press, Washington, DC, 1993.
M. Mahmoudi, M. Hefazi, M. Rastin and M. Balali-Mood. “Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans”. International Immunopharmacology, vol. 5, no. 9, pp. 1479-1485, 2005.
H. Mohammed, D. Jaff and S. Schrock. “The challenges impeding traffic safety improvements in the Kurdistan Region of Iraq”. Transportation Research Interdisciplinary Perspectives, vol. 2, p. 100029, 2019.
CDC. “Clinical Testing and Diagnosis for Hepatitis B”. CDC, United States, 2025.
R. T. Mohsen, R. H. Al-Azzawi and A. H. Ad’hiah. “Hepatitis B virus genotypes among chronic hepatitis B patients from Baghdad, Iraq and their impact on liver function”. Gene Reports, vol. 17, p. 100548, 2019.
CDC. “Clinical Screening and Diagnosis for Hepatitis C”. CDC, United States, 2025.
A. Al-Rubaye, Z. Tariq and L. Alrubaiy. “Prevalence of hepatitis B seromarkers and hepatitis C antibodies in blood donors in Basra, Iraq”. BMJ Open Gastroenterology, vol. 3, no. 1, p. e000067, 2016.
WHO. “Hepatitis D Fact Sheet”. WHO, Geneva, 2025.
M. R. Brunetto, G. Ricco, F. Negro, H. Wedemeyer, C. Yurdaydin, T. Asselah, G. Papatheodoridis, L. Gheorghe, K. Agarwal, P. Farci and M. Buti. “EASL clinical practice guidelines on hepatitis delta virus”. Journal of Hepatology, vol. 79, no. 2, pp. 433-460, 2023.
CDC. “Laboratory Testing for Epstein-Barr Virus (EBV)”. CDC, United States, 2024.
M. Zuhair, G. S. Smit, G. Wallis, F. Jabbar, C. Smith, B. Devleesschauwer and P. Griffiths. “Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis”. Reviews in Medical Virology, vol. 29, no. 3, p. e2034, 2019.
S. Samuel, S. Thomas, L. Asleson, A. Nguyen, J. L. Meier and R. El-Herte. “Deciphering positive cytomegalovirus immunoglobulin M test results in immunocompetent adults hospitalized with illness suspicious for acute cytomegalovirus infection: A multihospital study”. Open Forum Infectious Diseases, vol. 12, no. 3, p. ofaf144, 2025.
M. Al-Turab and W. Chehadeh. “Varicella infection in the Middle East: Prevalence, complications, and vaccination”. Journal of Research in Medical Sciences, vol. 23, no. 1, p. 19, 2018.
CDC. “Laboratory Testing for Varicella-Zoster Virus (VZV)”. CDC, United States, 2024.
S. Namazi, H. Niknahad and H. Razmkhah. “Long-term complications of sulphur mustard poisoning in intoxicated Iranian veterans”. Journal of Medical Toxicology, vol. 5, no. 4, pp. 191- 195, 2009.
WHO. “Hepatitis B Fact Sheet”. WHO, Geneva, 2025.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Gasha S. Ahmed, Hawbash M. Rahim, Salih A. Hama

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
